IMATINIB ACCORD 400 mg, film-coated tablet 30 tablets, CIP 3400930059654
Active ingredients: Imatinib, Imatinib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tablets, CIP 3400930059654orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMATINIB ACCORD 400 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) thermoformée(s) PVC PVDC aluminium de 1 comprimé(s)
- Marketing authorisation holder
- ACCORD HEALTHCARE (ESPAGNE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Oct 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66687082CIP73005965CIP133400930059654Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IMATINIBcomprimé | 400 mg · un comprimé | FT |
| MÉSILATE D'IMATINIBcomprimé | 478,000 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.